MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Comparison of olfactory testing and PSG for detection of alpha-synuclein pathology in patients with dream enactment behavior or REM sleep behavior disorder

    E. Brown, L. Chahine, A. Siderowf, C. Gochanour, C. Caspell-Garcia, M. Brumm, M. Marshall, C. Stanley, C. Soto, L. Concha, T. Sherer, T. Tanner, T. Simuni, K. Marek (San Francisco, USA)

    Objective: To compare the proportion of people with abnormal alpha-synuclein among groups with differing levels of certainty of REM sleep behavior disorder (RBD). Background: REM…
  • 2024 International Congress

    Continuous Subcutaneous Apomorphine Infusion for Parkinson Disease Motor Fluctuations: Long-Term Data from the Ongoing InfusON Extension Study

    P. Lewitt, S. Isaacson, A. Espay, S. Reyes, A. Formella, G. Ceresoli-Borroni (Detroit, USA)

    Objective: Evaluate outcomes (up to 3 years) from the ongoing Extension Period of the InfusON study (NCT02339064) of continuous subcutaneous apomorphine infusion (CSAI). Background: Primary…
  • 2024 International Congress

    Characterisation of the pharmacokinetic profile of amantadine in the common marmoset

    D. Bédard, F. Gaudette, S. Nuara, F. Beaudry, P. Huot (Montreal, Canada)

    Objective: To determine the pharmacokinetic (PK) profile of amantadine in the common marmoset (Callithrix jacchus). Background: Amantadine is currently approved for the treatment of L-3,4-dihydroxyphenylalanine…
  • 2024 International Congress

    Neurotinib, a Brain Penetrant c-Abl Inhibitor, Prevents Activation and Phosphorylation of c-Abl Kinase and Alpha-Synuclein

    N. Tayebi, B. Berhe, B. Aleksandra, J. Lichtenberg, A. D'Souza, M. Henderson, T. Chen, A. Alvarez, S. Zanlungo, M. Cookson, J. Marugan, E. Sidransky (Bethesda, USA)

    Objective: Objective: To investigate Neurotinib, a newly developed allosteric c-Abl inhibitor, as a neuroprotective agent in a murine GBA1-associated Parkinson's disease (PD) model. Background: The…
  • 2024 International Congress

    The impact of multimodal forms of art therapy on treatment outcomes and quality of life in Parkinson’s disease

    L. čondić Jurjević, S. Telarović (Sisak, Croatia)

    Objective: Assessing the impact of art therapy on treatment outcomes and quality of life in Parkinson's disease (PD). Background: In addition to medical treatment, art…
  • 2024 International Congress

    Exploring Non-Invasive Wearable Devices in Home Settings for Assessment and Treatment of the Duration of ON and OFF State and Freezing of Gait in Parkinson’s Disease: A Case Study.

    V. Azoidou, A. Noyce, C. Simonet, A. Mackett (London, United Kingdom)

    Objective: To assess the effect of cueing with vibrotactile stimulation on the duration of ON and OFF state and freezing of gait (FOG) in patients…
  • 2024 International Congress

    The international validation of the “Stepped Care” toolkit for comprehensive real life clinical care: bridging massive unmet need in care of Parkinson’s disease.

    K. Poplawska-Domaszewicz, MA. Qamar, L. Batzu, A. Shalash, Y. Lau, C. Falup-Pecurariu, A. Rekik, I. Boura, C. Spanaki, J. Chacko, C. Rodriguez-Blazquez, D. Urso, R. van Coller, D. Trivedi, V. Leta, W. Kozubski, S. Michalak, J. Slawek, C. Padmakumar, S. Gangadharan, K. Koh, C. Lazacano-Ocampo, A. Sauerbier, H. Dafsari, Y. Tsuboi, N. Mostyn, K. Ray Chaudhuri (Poznan, Poland)

    Objective: To conduct a cognitive pretesting of a global, cross-cultural, multicentre (14 countries) Stepped Care clinical toolkit. The questionnaire is completed by the healthcare professional…
  • 2024 International Congress

    Clinical characteristics associated with early discontinuation of Levodopa-Carbidopa Intestinal Gel infusion in patients with advanced Parkinson Disease.

    D. Rivero-Rodríguez, M. Morales-Casado, G. Tabar-Comellas, A. Diezma-Martín, P. Quintana-Castro, M. Ennazeh, N. López-Ariztegui (Toledo, Spain)

    Objective: To determine the clinical characteristics associated with early withdrawal of Levodopa-Carbidopa Intestinal Gel infusion (LCIG) in patients with advanced Parkinson´s Disease (APD) Background: LCIG…
  • 2024 International Congress

    Evaluating Clinical Practices of General Neurologists and Movement Disorder Specialists Based on 2020 AAN Parkinson Disease Quality Metrics

    C. Marshall, P. Vaswani (Philadelphia, USA)

    Objective: To evaluate and compare clinical practices of providers caring for patients with Parkinson’s disease utilizing searchable proxies of published quality metrics. Background: In 2020,…
  • 2024 International Congress

    Role of RNA splicing in Parkinson’s disease

    K. Irmady, C. Hale, R. Qadri, J. Fak, T. Carroll, R. Darnell (New York, USA)

    Objective: To identify key molecular perturbations affecting medium spiny neuron functions and their role in the clinical symptoms of Parkinson’s disease (PD). Background: The degeneration…
  • « Previous Page
  • 1
  • …
  • 116
  • 117
  • 118
  • 119
  • 120
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • VIT-D and Tics Movement Disorder
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley